These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 33376150)

  • 1. Identification of a Human Whole Blood-Based Endothelial Cell Impedance Assay for Assessing Clinical Transient Receptor Potential Vanilloid 4 Target Engagement Ex Vivo.
    Xu X; Goyal N; Costell MH; Roethke T; James CH; Thorneloe KS; Patterson J; Stoy P; Goodman K; Sprecher DL; Behm DJ
    J Pharmacol Exp Ther; 2021 Mar; 376(3):436-443. PubMed ID: 33376150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigating the effect of TRPV4 inhibition on pulmonary-vascular barrier permeability following segmental endotoxin challenge.
    Mole S; Harry A; Fowler A; Hotee S; Warburton J; Waite S; Beerahee M; Behm DJ; Badorrek P; Müller M; Faulenbach C; Lazaar AL; Hohlfeld JM
    Pulm Pharmacol Ther; 2020 Oct; 64():101977. PubMed ID: 33189900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Pharmacokinetics, Safety, and Tolerability of a Novel, First-in-Class TRPV4 Ion Channel Inhibitor, GSK2798745, in Healthy and Heart Failure Subjects.
    Goyal N; Skrdla P; Schroyer R; Kumar S; Fernando D; Oughton A; Norton N; Sprecher DL; Cheriyan J
    Am J Cardiovasc Drugs; 2019 Jun; 19(3):335-342. PubMed ID: 30637626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TRPV4 antagonists: a patent review (2015-2020).
    Lawhorn BG; Brnardic EJ; Behm DJ
    Expert Opin Ther Pat; 2021 Sep; 31(9):773-784. PubMed ID: 33724130
    [No Abstract]   [Full Text] [Related]  

  • 5. Targeting pulmonary capillary permeability to reduce lung congestion in heart failure: a randomized, controlled pilot trial.
    Stewart GM; Johnson BD; Sprecher DL; Reddy YNV; Obokata M; Goldsmith S; Bart B; Oughton A; Fillmore C; Behm DJ; Borlaug BA
    Eur J Heart Fail; 2020 Sep; 22(9):1641-1645. PubMed ID: 32227554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An orally active TRPV4 channel blocker prevents and resolves pulmonary edema induced by heart failure.
    Thorneloe KS; Cheung M; Bao W; Alsaid H; Lenhard S; Jian MY; Costell M; Maniscalco-Hauk K; Krawiec JA; Olzinski A; Gordon E; Lozinskaya I; Elefante L; Qin P; Matasic DS; James C; Tunstead J; Donovan B; Kallal L; Waszkiewicz A; Vaidya K; Davenport EA; Larkin J; Burgert M; Casillas LN; Marquis RW; Ye G; Eidam HS; Goodman KB; Toomey JR; Roethke TJ; Jucker BM; Schnackenberg CG; Townsley MI; Lepore JJ; Willette RN
    Sci Transl Med; 2012 Nov; 4(159):159ra148. PubMed ID: 23136043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of TRPV4 Antagonist GSK2798745 on Chlorine Gas-Induced Acute Lung Injury in a Swine Model.
    Vermillion MS; Saari N; Bray M; Nelson AM; Bullard RL; Rudolph K; Gigliotti AP; Brendler J; Jantzi J; Kuehl PJ; McDonald JD; Burgert ME; Weber W; Sucoloski S; Behm DJ
    Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcium-activated Potassium Channels as Amplifiers of TRPV4-mediated Pulmonary Edema Formation in Male Mice.
    Li M; Roeder J; Blázquez-Prieto J; Schulz S; Naujox J; Falivene J; Erfinanda L; Liedtke W; Albaiceta GM; Kuebler WM; Michalick L
    Anesthesiology; 2024 Nov; 141(5):913-928. PubMed ID: 39042042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TRPV4 channel activation induces the transition of venous and arterial endothelial cells toward a pro-inflammatory phenotype.
    Beddek K; Raffin F; Borgel D; Saller F; Riccobono D; Bobe R; Boittin FX
    Physiol Rep; 2021 Feb; 9(3):e14613. PubMed ID: 33512067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcium influx through TRPV4 channels modulates the adherens contacts between retinal microvascular endothelial cells.
    Phuong TTT; Redmon SN; Yarishkin O; Winter JM; Li DY; Križaj D
    J Physiol; 2017 Nov; 595(22):6869-6885. PubMed ID: 28949006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TRPV4 channels promote vascular permeability in retinal vascular disease.
    Nishinaka A; Tanaka M; Ohara K; Sugaru E; Shishido Y; Sugiura A; Moriguchi Y; Toui A; Nakamura S; Shimada K; Watanabe S; Hara H; Shimazawa M
    Exp Eye Res; 2023 Mar; 228():109405. PubMed ID: 36773739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transient receptor potential vanilloid 4 activation constricts the human bronchus via the release of cysteinyl leukotrienes.
    McAlexander MA; Luttmann MA; Hunsberger GE; Undem BJ
    J Pharmacol Exp Ther; 2014 Apr; 349(1):118-25. PubMed ID: 24504097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serotonin-induced vascular permeability is mediated by transient receptor potential vanilloid 4 in the airways and upper gastrointestinal tract of mice.
    Retamal JS; Grace MS; Dill LK; Ramirez-Garcia P; Peng S; Gondin AB; Bennetts F; Alvi S; Rajasekhar P; Almazi JG; Carbone SE; Bunnett NW; Davis TP; Veldhuis NA; Poole DP; McIntyre P
    Lab Invest; 2021 Jul; 101(7):851-864. PubMed ID: 33859334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The transient receptor potential vanilloid 4 (TRPV4) ion channel mediates protease activated receptor 1 (PAR1)-induced vascular hyperpermeability.
    Peng S; Grace MS; Gondin AB; Retamal JS; Dill L; Darby W; Bunnett NW; Abogadie FC; Carbone SE; Tigani T; Davis TP; Poole DP; Veldhuis NA; McIntyre P
    Lab Invest; 2020 Aug; 100(8):1057-1067. PubMed ID: 32341518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Transient Receptor Potential Vanilloid 4 in Neutrophil Activation and Acute Lung Injury.
    Yin J; Michalick L; Tang C; Tabuchi A; Goldenberg N; Dan Q; Awwad K; Wang L; Erfinanda L; Nouailles G; Witzenrath M; Vogelzang A; Lv L; Lee WL; Zhang H; Rotstein O; Kapus A; Szaszi K; Fleming I; Liedtke WB; Kuppe H; Kuebler WM
    Am J Respir Cell Mol Biol; 2016 Mar; 54(3):370-83. PubMed ID: 26222277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of GSK2789917-induced TRPV4 inhibition in animal models of fluid induced lung injury.
    Bihari S; Costell MH; Bouchier T; Behm DJ; Burgert M; Ye G; Bersten AD; Puukila S; Cavallaro E; Sprecher DL; Dixon DL
    Naunyn Schmiedebergs Arch Pharmacol; 2024 May; 397(5):3461-3475. PubMed ID: 37966569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of GSK2798745: A Clinical Candidate for Inhibition of Transient Receptor Potential Vanilloid 4 (TRPV4).
    Brooks CA; Barton LS; Behm DJ; Eidam HS; Fox RM; Hammond M; Hoang TH; Holt DA; Hilfiker MA; Lawhorn BG; Patterson JR; Stoy P; Roethke TJ; Ye G; Zhao S; Thorneloe KS; Goodman KB; Cheung M
    ACS Med Chem Lett; 2019 Aug; 10(8):1228-1233. PubMed ID: 31413810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological Inhibition of Transient Receptor Potential Vanilloid 4 Reduces Vasogenic Edema after Traumatic Brain Injury in Mice.
    Michinaga S; Onishi K; Shimizu K; Mizuguchi H; Hishinuma S
    Biol Pharm Bull; 2021; 44(11):1759-1766. PubMed ID: 34719652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adaptive study design to assess effect of TRPV4 inhibition in patients with chronic cough.
    Ludbrook VJ; Hanrott KE; Kreindler JL; Marks-Konczalik JE; Bird NP; Hewens DA; Beerahee M; Behm DJ; Morice A; McGarvey L; Parker SM; Birring SS; Smith J
    ERJ Open Res; 2021 Jul; 7(3):. PubMed ID: 34350286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Negative-feedback loop attenuates hydrostatic lung edema via a cGMP-dependent regulation of transient receptor potential vanilloid 4.
    Yin J; Hoffmann J; Kaestle SM; Neye N; Wang L; Baeurle J; Liedtke W; Wu S; Kuppe H; Pries AR; Kuebler WM
    Circ Res; 2008 Apr; 102(8):966-74. PubMed ID: 18323527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.